These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

38 related articles for article (PubMed ID: 711134)

  • 1. Dynamic evaluation of prolactin secretion with perphenazine in normal and hyperprolactinemic subjects.
    Buckman MT; Peake GT
    Horm Metab Res; 1978 Sep; 10(5):400-8. PubMed ID: 711134
    [No Abstract]   [Full Text] [Related]  

  • 2. Prolactin response to perphenazine. A sensitive and specific test for pituitary tumor in hyperprolactinemic women.
    Mattox JH; Fortunato SJ
    J Reprod Med; 1986 Dec; 31(12):1098-101. PubMed ID: 3795197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metoclopramide challenge: a measure of human lactotroph activity.
    Martin RH
    Obstet Gynecol; 1983 Dec; 62(6):691-5. PubMed ID: 6633994
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Use of bromocriptine as a diagnostic and therapeutic tool in hyperprolactinemic states.
    Abraham G
    Prog Clin Biol Res; 1982; 112 Pt A():255-73. PubMed ID: 7163300
    [No Abstract]   [Full Text] [Related]  

  • 5. [Bromocryptin therapy of hyperprolactinemic changes in the cycle].
    Volpe A; Oliva A; Baviera G; Grasso A; Maccarrone G; Montanari GD
    Boll Soc Ital Biol Sper; 1978 Sep; 54(18):1686-92. PubMed ID: 572687
    [No Abstract]   [Full Text] [Related]  

  • 6. Indomethacin fails to alter basal or phenothiazine-induced prolactin concentrations in man.
    Buckman MT; Peake GT; Srivastava S
    Horm Metab Res; 1979 Jun; 11(6):395-8. PubMed ID: 468103
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis of prolactin secreting pituitary tumor. Clinical analysis of 45 cases.
    Zheng ZS; Zhong XL; Sha SL; Yang DT; Zhang FL; Zhong CS
    Chin Med J (Engl); 1987 Aug; 100(8):639-44. PubMed ID: 3129245
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of central nervous system dopaminergic activation on prolactin secretion in man: evidence for a common central defect in hyperprolactinemic patients with and without radiological signs of pituitary tumors.
    Crosignani PG; Ferrari C; Malinverni A; Barbieri C; Mattei AM; Caldara R; Rocchetti M
    J Clin Endocrinol Metab; 1980 Nov; 51(5):1068-73. PubMed ID: 7419682
    [No Abstract]   [Full Text] [Related]  

  • 9. Approach to the diagnosis of hyperprolactinemic states: the nomifensine and domperidone tests.
    Molinatti GM; Camanni F; Cocchi D; De Leo V; Genazzni AR; Massara F; Muller EE
    Panminerva Med; 1981; 23(1):5-10. PubMed ID: 7290727
    [No Abstract]   [Full Text] [Related]  

  • 10. Concordance of insulin-induced hypoglycemia and phenothiazine-induced prolactin secretion in man.
    Buckman MT; Peake GT
    J Clin Endocrinol Metab; 1979 Feb; 48(2):213-6. PubMed ID: 429475
    [No Abstract]   [Full Text] [Related]  

  • 11. Restoration of prolactin synthesis and release by the administration of monoaminergic blocking agents to pituitary tumor-bearing rats.
    MacLeod RM; Lehmeyer JE
    Cancer Res; 1974 Feb; 34(2):345-50. PubMed ID: 4810907
    [No Abstract]   [Full Text] [Related]  

  • 12. Update on the diagnosis and management of prolactin-secreting pituitary adenomas, case reports.
    Fayez JA; Sowers JR; Blanchard S; Finnie BY; Morris T
    Mo Med; 1979 Sep; 76(9):492-6. PubMed ID: 503012
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of L-tryptophan on growth hormone and prolactin release in normal volunteers and patients with secretory pituitary tumors.
    Fraser WM; Tucker HS; Grubb SR; Wigand JP; Blackard WG
    Horm Metab Res; 1979 Feb; 11(2):149-55. PubMed ID: 437678
    [No Abstract]   [Full Text] [Related]  

  • 14. Loss of central nervous system component of dopaminergic inhibition of prolactin secretion in patients with prolactin-secreting pituitary tumors.
    Fine SA; Frohman LA
    J Clin Invest; 1978 Apr; 61(4):973-80. PubMed ID: 659585
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum prolactin level increase in normal subjects following administration of perphenazine oral dosage forms: possible application to bioavailability testing.
    Erb RJ; Stoltman WP
    J Pharm Sci; 1982 Aug; 71(8):883-8. PubMed ID: 7120089
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum prolactin levels in patients with gynecomastia.
    Turkington RW
    J Clin Endocrinol Metab; 1972 Jan; 34(1):62-6. PubMed ID: 5061776
    [No Abstract]   [Full Text] [Related]  

  • 17. Interpreting prolactin levels.
    Lancet; 1987 Dec; 2(8573):1457-8. PubMed ID: 2892012
    [No Abstract]   [Full Text] [Related]  

  • 18. Prolactin and blood pressure responses to perphenazine in human subjects: comparison of the oral and intramuscular routes.
    Musey VC; Preedy JR; Musey PI; Blank MS; Brogan DR; Bain RP; Collins DC
    Am J Med Sci; 1986 Jun; 291(6):380-5. PubMed ID: 3717195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Estrogen therapy for the hyperprolactinemic postmenopause woman].
    Münster K; Petersen H
    Ugeskr Laeger; 1983 Apr; 145(14):1068-9. PubMed ID: 6868157
    [No Abstract]   [Full Text] [Related]  

  • 20. [Diagnosis and treatment of pituitary prolactinoma].
    Lu YR
    Zhonghua Yi Xue Za Zhi; 1983 Dec; 63(12):730-3. PubMed ID: 6426742
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 2.